secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2024-01-11T23:59:59+00:00
Accession:  0001367644-24-000004
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions wins $235.8M DoD contract for BioThrax anthrax vaccine
----------------------------------------------------------------------------

- IDIQ contract with U.S. DoD and JPEO-CBRND valued up to $235.8M to supply BioThrax for military PrEP.
- Contract includes 5-year base ending Sep 30, 2028, plus a 5-year option extending to Sep 30, 2033.
- Guaranteed minimum purchase of $20.1M in first year; estimated at least $20M per year thereafter.
- Paul Williams, senior VP products head, notes contract reinforces Emergent's medical countermeasures portfolio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764424000004/0001367644-24-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764424000004/ebs-20240109.htm
  HTML page:      https://secwatch.observer/filing/0001367644-24-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer